An Psoriasis In HIV Patients: A Paradox

Psoriasis In HIV Patients: A Paradox

Authors

  • Nita Damayanti Universitas Gadjah Mada
  • Satiti Retno Pudjiati Department of Dermatology and Venereology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia Gedung Radiopoetro lantai 3, Jl. Farmako Sekip Utara, Senolowo, Sinduadi, Kec. Mlati, Kabupaten Sleman, Daerah Istimewa Yogyakarta 55281, Indonesia

DOI:

https://doi.org/10.66344/jpad.32.1.2022.1846

Abstract

Introduction: Human immunodeficiency virus (HIV) infection is associated with increased susceptibility to skin disorders, including psoriasis. The exacerbation of psoriasis in severe advanced HIV is paradoxical. Case: a 26-year-old man with HIV who had been diagnosed with psoriasis ten months before the diagnosis of HIV. The skin biopsy results indicated psoriasis vulgaris with a tissue CD4/CD8 ratio of 0/34. The initial CD4 count was 130 cells/L. The patient received ARV and topical steroids. There was a clinically significant rise in blood CD4 and tissue CD4/CD8 ratio in three-month follow-up. Discussion: There are several hypotheses was proposed to explain the pathophysiology of psoriasis in HIV. The main therapy of psoriasis with HIV is ARV. Conclusion:  HIV can induce or as a risk factor of psoriasis. It's important to do a search further for risk factors in sexually transmitted diseases in patients with severe and recalcitrant psoriasis. The main therapy of psoriasis with HIV is ARV. 

Downloads

Published

2022-03-29

How to Cite

1.
Damayanti N, Pudjiati S. An Psoriasis In HIV Patients: A Paradox: Psoriasis In HIV Patients: A Paradox. J Pak Assoc Dermatol [Internet]. 2022Mar.29 [cited 2026Apr.12];32(1):214-7. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1846

Issue

Vol. 32 No. 1 (2022): January - March

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.